REG-Bioventix Plc: Director/PDMR Shareholding <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

30/04/2015 07:00

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                               Director dealing                                

Bioventix plc (AIM: BVXP) was notified on 29 April 2015 that on the same day,
due to institutional investor demand, Peter Harrison, Chief Executive of the
Company, sold 53,000 ordinary shares of 5 pence each ("Ordinary Shares") in the
Company at a price of 800 pence per Ordinary Share (the "Sale"). Following the
Sale, Mr Harrison holds 608,176 Ordinary Shares, representing 12.0% of the
issued share capital of the Company.

Mr Harrison and associated persons have agreed not to dispose of any additional
Ordinary Shares for a period of 12 months.

For further information please contact:

Bioventix plc                     
Peter Harrison             Chief Executive Officer    Tel: 01252 728 001
                                                                               
finnCap Ltd                                           Tel: 020 7220 0500       
Geoff Nash/Simon Hicks     Corporate Finance                                   
Steve Norcross             Corporate Broking                                                    

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



END



Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved